{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:08:34Z","timestamp":1782846514744,"version":"3.54.5"},"reference-count":32,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec sec-type=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson disease (PD), a progressive neurodegenerative disorder, lacks disease-modifying treatments. Current therapies focus on symptomatic relief, highlighting the need for adjunctive neuroprotective strategies. Ayurveda, a holistic system, shows promise in improving PD clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"objective\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This assessor-blinded randomized controlled study aims to systematically evaluate the efficacy of an add-on Ayurveda therapeutic regimen compared to conventional treatment as usual (TAU) in improving the clinical outcomes of PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 80 patients with PD, diagnosed according to UK Parkinson\u2019s Disease Society Brain Bank criteria, will be randomized into two groups: TAU and add-on Ayurveda. The intervention group will receive Ayurvedic therapy alongside conventional treatment for 180 days, whereas the control group will continue TAU. Assessments will occur at baseline and at 60-, 120-, and 180-day follow-ups, evaluating motor and nonmotor symptoms. Transcranial magnetic stimulation, heart rate variability, and pulmonary function tests will assess cortical excitability, autonomic function, and pulmonary function, respectively. Immunological parameters, including cytokine levels and telomere length, will be analyzed at baseline and at 180 days to explore disease-modifying effects. Liver and renal function tests will monitor safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      As of 2025, a total of 259 patients with PD have been screened for eligibility, of whom 58\n                      <jats:sup\/>\n                      participants have been successfully enrolled in the trial. Among these,\n                      <jats:sup\/>\n                      33 participants have completed the intervention and follow-up assessments,\n                      <jats:sup\/>\n                      14 have discontinued participation, and\n                      <jats:sup\/>\n                      11 are currently continuing participation in the study. Recruitment and follow-up are ongoing, and the trial is scheduled for completion in September 2026.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study aims to address the lack of mechanistic evidence and robust data on Ayurveda in PD. By systematically evaluating clinical efficacy and potential biomechanisms, the findings will provide preliminary evidence for Ayurvedic interventions, potentially paving the way for their integration into comprehensive PD management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/83336","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T08:35:06Z","timestamp":1763109306000},"page":"e83336-e83336","source":"Crossref","is-referenced-by-count":0,"title":["Ayurvedic Therapeutic Regimen as an Add-On to Optimized Conventional Management of Parkinson Disease: Protocol for an Exploratory Randomized Controlled Trial Evaluating Clinical, Cortical Excitability, Neuroimmune, and Autonomic Function Parameters"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0788-1181","authenticated-orcid":false,"given":"Umesh","family":"Chikkanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-2377","authenticated-orcid":false,"given":"Pramod Kumar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-3610","authenticated-orcid":false,"given":"Sophia","family":"Jameela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-4569","authenticated-orcid":false,"given":"Rohan R","family":"Mahale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7933-8826","authenticated-orcid":false,"given":"Nitish","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0353-8597","authenticated-orcid":false,"given":"Venkataram","family":"Shivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-1237","authenticated-orcid":false,"given":"Bharath","family":"Holla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8016-9089","authenticated-orcid":false,"given":"Ravi","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3634-2219","authenticated-orcid":false,"given":"Vikram V","family":"Holla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9865-0586","authenticated-orcid":false,"given":"Talakad Narasappa","family":"Sathyaprabha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6906-5193","authenticated-orcid":false,"given":"Kaviraja","family":"Udupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4133-4931","authenticated-orcid":false,"given":"Srinibash","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3908-7222","authenticated-orcid":false,"given":"Manjunath M","family":"Venkataswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8891-7192","authenticated-orcid":false,"given":"Selva","family":"Ganapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5408-3225","authenticated-orcid":false,"given":"Chandra Shekara","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9827-4119","authenticated-orcid":false,"given":"Babita","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5635-1296","authenticated-orcid":false,"given":"Sreenithya","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1420-8606","authenticated-orcid":false,"given":"Shivarama","family":"Varambally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9828-0658","authenticated-orcid":false,"given":"Sulochana","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3976-4978","authenticated-orcid":false,"given":"Narayanam","family":"Srikanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-274X","authenticated-orcid":false,"given":"Kishore Kumar","family":"Ramakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"4","key":"R1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson\u2019s disease: clinical features and diagnosis","volume":"79","author":"Jankovic","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl","key":"R2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/jnnp.52.suppl.6","article-title":"Aspects of the history of Parkinson\u2019s disease","volume":"Suppl","author":"Pearce","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 2","key":"R3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s1353-8020(03)00024-5","article-title":"Epidemiology and treatment of Parkinson\u2019s disease in India","volume":"9","author":"Singhal","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"R4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000110368","article-title":"Prevalence and pattern of major neurological disorders in rural Kashmir (India) in 1986","volume":"13","author":"Razdan","journal-title":"Neuroepidemiology"},{"issue":"12","key":"R5","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1001\/archneur.1988.00520360039008","article-title":"Prevalence of Parkinson\u2019s disease in the Parsi community of Bombay, India","volume":"45","author":"Bharucha","journal-title":"Arch Neurol"},{"issue":"3","key":"R6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3233\/JPD-191683","article-title":"Parkinson\u2019s disease in women and men: what\u2019s the difference?","volume":"9","author":"Cerri","journal-title":"J Parkinsons Dis"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-006-0546-6","article-title":"Parkinson\u2019s disease and dementia","volume":"27 Suppl 1","author":"Padovani","journal-title":"Neurol Sci"},{"issue":"4","key":"R8","doi-asserted-by":"publisher","DOI":"10.3390\/biom11040612","article-title":"Treatment options for motor and non-motor symptoms of Parkinson\u2019s disease","volume":"11","author":"Church","journal-title":"Biomolecules"},{"issue":"13","key":"R9","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1517\/14656566.7.13.1715","article-title":"Levodopa, motor fluctuations and dyskinesia in Parkinson\u2019s disease","volume":"7","author":"M\u00fcller","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"R10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/s1353-8020(01)00024-4","article-title":"Motor fluctuations and dyskinesia in Parkinson\u2019s disease","volume":"8","author":"Nutt","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"R11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jtcme.2015.03.009","article-title":"Complementary and alternative medicine in Indian Parkinson\u2019s disease patients","volume":"6","author":"Pandit","journal-title":"J Tradit Complement Med"},{"issue":"10","key":"R12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.93992","article-title":"Exploring Ayurveda\u2019s potential in Parkinson\u2019s disease: a comprehensive narrative","volume":"17","author":"Chikkanna","journal-title":"Cureus"},{"key":"R13","unstructured":"Agnivesa. Chikitsa sthana, vatavyadhichikitsa. In: Charaka Samhita. Chaukambha Sanskrit Pratishthan; 2017:616. URL: https:\/\/niimh.nic.in\/ebooks\/ecaraka\/?mod=read [Accessed 06-01-2026]"},{"key":"R14","unstructured":"Subject: draft guideilnes on good clinical practices - regarding. ICMR Bioethics Unit. Sep 12, 2024. URL: https:\/\/ethics.ncdirindia.org\/asset\/pdf\/Indian_GCP_guideline.pdf [Accessed 06-01-2026]"},{"issue":"6","key":"R15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","article-title":"Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis","volume":"86","author":"Rizzo","journal-title":"Neurology (ECronicon)"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120078","article-title":"Efficacy and safety of istradefylline in patients with Parkinson\u2019s disease presenting with postural abnormalities: results from a multicenter, prospective, and open-label exploratory study in Japan","volume":"432","author":"Takahashi","journal-title":"J Neurol Sci"},{"issue":"20","key":"R17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","journal-title":"JAMA"},{"issue":"10","key":"R18","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/mds.25122","article-title":"Calibration of unified Parkinson\u2019s disease rating scale scores to movement disorder society-unified Parkinson\u2019s disease rating scale scores","volume":"27","author":"Goetz","journal-title":"Mov Disord"},{"issue":"3","key":"R19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/mds.25321","article-title":"Which dyskinesia scale best detects treatment response?","volume":"28","author":"Goetz","journal-title":"Mov Disord"},{"issue":"10","key":"R20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.33588\/rn.4310.2006307","article-title":"Estudio piloto sobre una medida espec\u00edfica para los trastornos del sue\u00f1o de la enfermedad de Parkinson: SCOPA-Sue\u00f1o [A pilot study on a specific measure for sleep disorders in Parkinson\u2019s disease: SCOPA-Sleep]","volume":"43","author":"Mart\u00ednez Mart\u00edn","journal-title":"Rev Neurol"},{"issue":"9","key":"R21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/jgs.15925","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","author":"Nasreddine","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"R22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/MRR.0000000000000205","article-title":"Clinical utility of the 6-min walk test for patients with moderate Parkinson\u2019s disease","volume":"40","author":"Kobayashi","journal-title":"Int J Rehabil Res"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaitpost.2016.11.033","article-title":"Are the average gait speeds during the 10 meter and 6 minute walk tests redundant in Parkinson disease?","volume":"52","author":"Duncan","journal-title":"Gait Posture"},{"issue":"3","key":"R24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/1941738111403122","article-title":"Systematic review of the balance error scoring system","volume":"3","author":"Bell","journal-title":"Sports Health"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2019.08.006","article-title":"Prediction of cognitive progression in Parkinson\u2019s disease using three cognitive screening measures","volume":"1","author":"Kim","journal-title":"Clin Park Relat Disord"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.25259\/IJPP_90_2020","article-title":"Transcranial magnetic stimulation in exploring neurophysiology of cortical circuits and potential clinical implications","volume":"64","author":"Udupa","journal-title":"IJPP"},{"key":"R27","unstructured":"Central council for research in ayurvedic sciences. URL: https:\/\/www.ccras.nic.in [Accessed 06-01-2026]"},{"issue":"1","key":"R28","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00321-y","article-title":"Mechanisms of peripheral levodopa resistance in Parkinson\u2019s disease","volume":"8","author":"Beckers","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"R29","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s00702-018-1876-2","article-title":"Monoamine oxidase-B inhibitors in the treatment of Parkinson\u2019s disease: clinical-pharmacological aspects","volume":"125","author":"Riederer","journal-title":"J Neural Transm (Vienna)"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1017\/s031716710000007x","article-title":"COMT inhibitors in Parkinson\u2019s disease","volume":"26 Suppl 2","author":"Rivest","journal-title":"Can J Neurol Sci"},{"issue":"10","key":"R31","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s40263-020-00754-0","article-title":"Non-dopaminergic treatments for motor control in Parkinson\u2019s disease: an update","volume":"34","author":"Gonzalez-Latapi","journal-title":"CNS Drugs"},{"issue":"3","key":"R32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.baga.2013.09.001","article-title":"Glutamate in Parkinson\u2019s disease: role of antiglutamatergic drugs","volume":"3","author":"Carrillo-Mora","journal-title":"Basal Ganglia"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e83336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:17:25Z","timestamp":1782843445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e83336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":32,"URL":"https:\/\/doi.org\/10.2196\/83336","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"v15i4e83336"}}